ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO Recognizes 15 for Leadership in Clinical Oncology, Updates Genetic Testing Recommendations

May 23, 2003

In Brief: Jensen, Selikoff Receive ACS National Awards; CCIRC Schedules Mini-Symposium

October 22, 1976

Nutrition Program Announcement Lists Suggested Areas For Research

September 22, 1978

In Brief: OMB tells NCI Mislead Congress, Refuses Higher Budget; Ford Says He Support Program

March 28, 1975

Xgeva Significantly Increases Bone Metastasis-Free Survival

May 27, 2011

PRI Drops Suit Against Top Two FCRF Staff; Gilden, Compton Accept “Partnership” Offers

August 22, 1986